Literature DB >> 21881324

The effect of sivelestat sodium hydrate on severe respiratory failure after thoracic aortic surgery with deep hypothermia.

Keisuke Morimoto1, Kengo Nishimura, Shigeto Miyasaka, Hiroyuki Maeta, Iwao Taniguchi.   

Abstract

Patients who undergo thoracic aortic surgery with deep hypothermia frequently have postoperative respiratory failure as a complication. Severe lung injury in these patients results in a fatal outcome. A specific neutrophil elastase inhibitor, sivelestat sodium hydrate, is an innovative therapeutic drug for acute lung injury. We evaluated the protective effects of sivelestat sodium hydrate on severe lung injury after thoracic aortic surgery with deep hypothermia. From January 2002 to July 2007, 71 consecutive patients underwent thoracic aortic surgery with deep hypothermia. Of these patients, 22 had postoperative respiratory failure with PaO₂/FiO₂ ratios of less than 150. They were randomly assigned to one of two groups. The first group (Group S, n = 10) was administered sivelestat sodium hydrate continuously at 0.2 mg/kg/h until weaning from mechanical ventilation; the second group (Group C, n = 12) was not administered sivelestat sodium hydrate. The groups were comparable with respect to clinical data. There were no significant differences between the two groups in age, operation duration, total cardiopulmonary bypass time, circulatory ischemia time, cardiac arrest time, intraoperative blood loss, and total transfusion volume. The improvement of pulmonary function was observed in the both groups, but more marked in Group S by statistical analysis using analysis of variance for repeated measurements. Especially, in the early phase, pulmonary function improvement was more marked in Group S. The duration of mechanical ventilation, the length of stay in the intensive care unit, and the length of hospital stay were shorter in Group S, but not significantly. Sivelestat sodium hydrate is a specific neutrophil elastase inhibitor that improves pulmonary function in patients with severe postoperative respiratory failure following thoracic aortic surgery with deep hypothermia. The drug may shorten the duration of postoperative ventilation, intensive care unit stay, and hospital stay.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881324     DOI: 10.5761/atcs.oa.10.01555

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  6 in total

1.  Emodin alleviates LPS-induced inflammatory response in lung injury rat by affecting the function of granulocytes.

Authors:  Hongxia Mei; Ying Tao; Tianhao Zhang; Feng Qi
Journal:  J Inflamm (Lond)       Date:  2020-08-08       Impact factor: 4.981

2.  Endovascular Repair versus Open Repair for Isolated Descending Thoracic Aortic Aneurysm.

Authors:  Hyung Chae Lee; Hyun-Chel Joo; Seung Hyun Lee; Sak Lee; Byung-Chul Chang; Kyung-Jong Yoo; Young-Nam Youn
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

3.  Predictors of the therapeutic effect of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome.

Authors:  Takuma Ozawa; Kiyoshi Mihara; Nobuhiro Yasuno
Journal:  J Pharm Health Care Sci       Date:  2016-08-24

4.  Alginate oligosaccharide indirectly affects toll-like receptor signaling via the inhibition of microRNA-29b in aneurysm patients after endovascular aortic repair.

Authors:  Yong Yang; Zhenhuan Ma; Guokai Yang; Jia Wan; Guojian Li; Lingjuan Du; Ping Lu
Journal:  Drug Des Devel Ther       Date:  2017-09-01       Impact factor: 4.162

5.  Effects of pulmonary static inflation with 50% xenon on oxygen impairment during cardiopulmonary bypass for stanford type A acute aortic dissection: A pilot study.

Authors:  Mu Jin; Yanwei Yang; Xudong Pan; Jiakai Lu; Zhiquan Zhang; Weiping Cheng
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Effect of sivelestat sodium in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of randomized controlled trials.

Authors:  Shenglan Pu; Daoxin Wang; Daishun Liu; Yan Zhao; Di Qi; Jing He; Guoqi Zhou
Journal:  BMC Pulm Med       Date:  2017-11-21       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.